Hall P D, Self S E, Hall R K
Pharmacotherapy. 1997 Mar-Apr;17(2):248-55.
To determine the long-term effects of maintenance interferon on CD56+ and CD3+ cell activity.
Prospective phase II trial.
Tertiary medical center and level 2 Veterans Administration hospital.
Seven patients (age 45-74 yrs) with multiple myeloma who had reached the plateau phase from cytotoxic chemotherapy, and seven age- and sex-matched controls.
All patients were given interferon-alpha 2b 3 x 10(6) U/m2 3 times/week.
The CD56+, CD3+, and CD16+ counts were determined by flow cytometry in both peripheral blood and bone marrow. Natural killer (NK) cell functional activity was determined by a 51chromium release assay. Monocyte cell numbers were determined from the white blood cell count with differential. Interleukin-6 (IL-6) concentrations were determined by a commercially available enzyme-linked immunosorbent assay. During the 24-week study, the peripheral blood CD3+ and monocyte counts in patients with myeloma remained constant (p > or = 0.39) but their absolute CD56+ counts decreased significantly (p = 0.05). In peripheral blood, CD56+, CD16-, CD3- was the predominant phenotype in patients. The predominant phenotype in bone marrow was CD56+, CD16-, CD3+ at baseline but changed to CD56+, CD16-, CD3- by week 24. The cytolytic activity of NK cells significantly increased in bone marrow (p = 0.05) whereas it remained stable in the peripheral blood (p = 0.55), but only half that of the controls. Concentrations of IL-6 did not increase significantly during the study.
In peripheral blood, NK cell activity remained stable in patients but was significantly lower than that in controls, probably secondary to the predominance of the CD56+, CD16-, CD3- phenotype in the patients. In contrast, NK cell activity increased significantly in bone marrow despite the predominance of the CD56+, CD16-, CD3- phenotype by week 24.
确定维持性干扰素对CD56+和CD3+细胞活性的长期影响。
前瞻性II期试验。
三级医疗中心和二级退伍军人管理局医院。
7例（年龄45 - 74岁）多发性骨髓瘤患者，已从细胞毒性化疗进入平台期，以及7例年龄和性别匹配的对照者。
所有患者均接受干扰素-α 2b 3×10(6) U/m2，每周3次。
通过流式细胞术测定外周血和骨髓中的CD56+、CD3+和CD16+计数。自然杀伤（NK）细胞功能活性通过51铬释放试验测定。单核细胞数量根据白细胞计数及分类确定。白细胞介素-6（IL-6）浓度通过市售酶联免疫吸附试验测定。在为期24周的研究中，骨髓瘤患者外周血中的CD3+和单核细胞计数保持恒定（p≥0.39），但其绝对CD56+计数显著下降（p = 0.05）。在外周血中，CD56+、CD16-、CD3-是患者的主要表型。骨髓中的主要表型在基线时为CD56+、CD16-、CD3+，但到第24周时变为CD56+、CD16-、CD3-。NK细胞的细胞溶解活性在骨髓中显著增加（p = 0.05），而在外周血中保持稳定（p = 0.55），但仅为对照者的一半。研究期间IL-6浓度未显著增加。
在外周血中，患者的NK细胞活性保持稳定，但显著低于对照者，这可能继发于患者中CD56+、CD16-、CD3-表型占优势。相比之下，尽管到第24周时CD56+、CD16-、CD3-表型占优势，但骨髓中的NK细胞活性仍显著增加。
